Advertisement

Picture [iito] Made Without Love 650x80px
Document › Details

Sirion Biotech GmbH. (1/7/21). "Press Release: Sirion Biotech GmbH Licensed Its LentiBoost Transduction Technology to Cellectis". Munich & Cambridge, MA.

Organisations Organisation Sirion Biotech GmbH
  Group Sirion Biotech (Group)
  Organisation 2 Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)
  Group Cellectis (Group)
Products Product LentiBoost™ technology (lentiviral transduction enhancer)
  Product 2 CAR-T technology (Chimeric Antigen Receptor T-Cell technology)
Index term Index term Cellectis–Sirion Biotech: cell/gene therapy manufacturing technology, 202101– non-excl license €na to LentiBoost technology for CAR-T cell therapies
Persons Person Thirion, Christian (Sirion Biotech 201106 Managing Director + Founder)
  Person 2 Ott, Sabine (Sirion Biotech 201604– VP Licensing + BusDev before GeneWake + MWG Biotech)
     


Through this license agreement, SIRION Biotech GmbH (“SIRION”) granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST™. This product complements Cellectis’ portfolio of technologies involved in manufacturing allogeneic CAR T-cells. SIRION is entitled to undisclosed upfront and milestone payments and is eligible to receive royalties on future product net sales plus license fees tied to commercial success.

Allogeneic CAR-T cell therapy represent a future-defining shift in simplicity, availability, and cost efficiency of immune-oncology approaches. Engineering effective allogeneic T-cells, in contrast to patient derived cells, elevates the technology to the level of a realistic off-the-shelf product.

Dr. Christian Thirion, CEO and founder of SIRION explains: “LentiBOOST™ improves lentiviral transduction of difficult cell types like hematopoietic stem cells, and in addition generates stable integration of large constructs generally needed to generate CAR-T cells.”

“We are delighted that our product will help further develop affordable allogeneic cancer treatments that will, once approved, benefit patients with unmet needs,” says SVP BD & Licensing, Dr. Sabine Ott.


About SIRION Biotech

SIRION Biotech began its customer business in 2007 in Munich, setting their goal to spark a new generation of viral vector technologies for gene and cell therapy as well as vaccination development. This meant building novel, all-encompassing viral vector platforms for lenti-, adeno-, and adeno-associated viruses which expedite its partners’ advances in drug, cosmetics, and food industries. To date SIRION has completed over 1500 projects of all sizes, working closely with over 200 independent customer groups from academia and industry.


Contacts

Corporate Contact
Dieter Lingelbach, COO
SIRION Biotech
+49 89-700-96199-14
lingelbach@sirion-biotech.com

Media Contact USA
Lisa DeScenza
Vice President, Integrated Communications
LaVoieHealthScience
(978) 395-5970
ldescenza@lavoiehealthscience.com

BD & Licensing Contact
Sabine Ott, Ph.D., Senior VP Licensing & BD
SIRION Biotech
+49 89-700-96199-13
ott@sirion-biotech.com

   
Record changed: 2021-04-27

Advertisement

Picture [iito] Made Without Love 650x80px

More documents for Sirion Biotech (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80




» top